Neuralstem in the News

 

  • “Stem cell therapy helps paraplegic rats regain movement”

By Selina McKee, PharmaTimes, September 17, 2012

NSI-566/spinal cord injury animal research, following report in the scientific journal CELL, is reported by UK-based industry publication.

View Article

  • “Paralyzed Rats Walk Again After Stem Cell Transplant:
    The rodent recovery spurs hope that humans could one day benefit from similar treatments.”

By Susan Young, Biomedicine Editor, Technology Review, published by MIT, September 13, 2012

Susan Young, who recently reported on progress of NSI-566 cell therapy in the ongoing ALS trial, examines CELL spinal cord injury research study, noting promise of both clinical and pre-clinical trials utilizing NSI-566 neural stem cells.

View Article

  • "Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats"

By Ryan Flinn, Bloomberg, September 13, 2012

“…the last piece of the puzzle…” to move Neuralstem’s human spinal cord injury trial forward is projected by Neuralstem’s CEO Richard Garr in this article focused on the SCI study published in scientific journal CELL.

View Article

  • "Stem Cells Help Rats Recover Lower-Body Movement"

By Alex Philippidis, Genetic Engineering & Biotechnology News, September 13, 2012

Neuralstem’s NSI-566 cells in spinal cord injury animal study, where six transplanted paraplegic rats recovered movement in all lower joints, is reported in GEN, following publication in the scientific journal CELL.

View Article

  • Neuralstem Overview Article by John H. Ford

By John H. Ford, Seeking Alpha, September 11, 2012

Comprehensive, to-the-minute overview article of Neuralstem’s progress in both its stem cell therapy and neurogenic pharmaceutical divisions. Includes promise of hope: “With all these indications, any level of success with these other incurable conditions could provide tremendous hope and relief for millions of patients.”

View Article

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

Privacy and Terms ©Neuralstem, Inc. 2013